Global Newsroom | CSL
网页CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU. Jun 11, 2024 - CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in …
News Releases - CSL
网页2 天之前 · CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU. CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have ...
News Releases - CSL
网页CSL enters into Strategic Option and License Agreement with Translational Sciences. Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced thrombus dissolving drug candidate, TS23. Oct 20, 2022.
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior …
网页2 天之前 · Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and Arcturus Therapeutics' commitment to advancing COVID-19 vaccine innovation to protect public health. WALTHAM, Mass. and SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Global biotechnology leader CSL ...
News Releases | CSL
网页2022年11月2日 · MELBOURNE, Australia and KING OF PRUSSIA, Pa., Nov. 2, 2022 / PRNewswire / -- At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health.
CSL Opens New, State-of-the-Art Vaccine Research and …
网页2023年3月27日 · The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines . WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC:CSLLY) today celebrated the official opening of the company's new state-of-the-art research and development (R&D) center in Waltham, Massachusetts.
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial ...
网页KING OF PRUSSIA, Pa., Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI).
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives …
网页2023年12月14日 · These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has been serving for over 40 years, in the U.S. and European Union.
CSL Announces Closing of Global Collaboration and Licensing …
网页2022年12月12日 · CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens...
CSL announces carbon emissions reduction targets
网页MELBOURNE, Australia, Aug. 16, 2022 / PRNewswire / -- CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions. As part of the company's broader sustainability strategy to build a more sustainable future for employees, communities, patients and donors ...